STEM CELL THERAPY AS A POTENTIAL TREATMENT FOR GLAUCOMA

T. S. Ramasamy, M. Kamal, F. Amini
{"title":"STEM CELL THERAPY AS A POTENTIAL TREATMENT FOR GLAUCOMA","authors":"T. S. Ramasamy, M. Kamal, F. Amini","doi":"10.22452/JUMMEC.VOL19NO1.4","DOIUrl":null,"url":null,"abstract":"Glaucoma is a common eye disease that can cause irreversible damage if left undiagnosed and untreated. It is one of the most common neurodegenerative diseases causing blindness. Pre-clinical studies have been carried out on animal models of glaucoma for stem cell therapy. We carried out a systematic review to determine whether stem cell therapy had the potential to treat glaucoma. Nine studies were selected based on the predetermined inclusion and exclusion criteria. Of these nine studies, eight focused on neuroprotection conferred by stem cells, and the remaining one on neuroregeneration. Results from these studies showed that there was a potential in stem cell based therapy in treating glaucoma, especially regarding neuroprotection via neurotrophic factors. The studies revealed that a brain-derived neurotrophic factor expressed by stem cells promoted the survival of retinal ganglion cells in murine glaucoma models. The transplanted cells survived without any side effects. While these studies proved that stem cells provided neuroprotection in glaucoma, improvement of vision could not be determined. Clinical studies would be required to determine whether the protection of RGC correlated with improvement in visual function. Furthermore, these murine studies could not be translated into clinical therapy due to the heterogeneity of the experimental methods and the use of different cell lines. In conclusion, the use of stem cells in the clinical therapy of glaucoma will be an important step in the future as it will transform present-day treatment with the hope of restoring sight to patients with glaucoma.","PeriodicalId":39135,"journal":{"name":"Journal of the University of Malaya Medical Centre","volume":"19 1","pages":"23-32"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the University of Malaya Medical Centre","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22452/JUMMEC.VOL19NO1.4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Glaucoma is a common eye disease that can cause irreversible damage if left undiagnosed and untreated. It is one of the most common neurodegenerative diseases causing blindness. Pre-clinical studies have been carried out on animal models of glaucoma for stem cell therapy. We carried out a systematic review to determine whether stem cell therapy had the potential to treat glaucoma. Nine studies were selected based on the predetermined inclusion and exclusion criteria. Of these nine studies, eight focused on neuroprotection conferred by stem cells, and the remaining one on neuroregeneration. Results from these studies showed that there was a potential in stem cell based therapy in treating glaucoma, especially regarding neuroprotection via neurotrophic factors. The studies revealed that a brain-derived neurotrophic factor expressed by stem cells promoted the survival of retinal ganglion cells in murine glaucoma models. The transplanted cells survived without any side effects. While these studies proved that stem cells provided neuroprotection in glaucoma, improvement of vision could not be determined. Clinical studies would be required to determine whether the protection of RGC correlated with improvement in visual function. Furthermore, these murine studies could not be translated into clinical therapy due to the heterogeneity of the experimental methods and the use of different cell lines. In conclusion, the use of stem cells in the clinical therapy of glaucoma will be an important step in the future as it will transform present-day treatment with the hope of restoring sight to patients with glaucoma.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
干细胞疗法作为青光眼的潜在治疗方法
青光眼是一种常见的眼部疾病,如果不及时诊断和治疗,可能会造成不可逆转的损害。它是导致失明的最常见的神经退行性疾病之一。在青光眼动物模型上进行了干细胞治疗的临床前研究。我们进行了一项系统综述,以确定干细胞疗法是否有治疗青光眼的潜力。根据预定的纳入和排除标准选择了9项研究。在这9项研究中,8项关注干细胞赋予的神经保护作用,其余1项关注神经再生。这些研究结果表明,干细胞治疗青光眼具有潜力,特别是通过神经营养因子的神经保护作用。研究表明,由干细胞表达的脑源性神经营养因子可促进小鼠青光眼模型视网膜神经节细胞的存活。移植的细胞存活了下来,没有任何副作用。虽然这些研究证明干细胞在青光眼中提供神经保护,但视力的改善还不能确定。需要临床研究来确定RGC的保护是否与视觉功能的改善相关。此外,由于实验方法的异质性和使用不同细胞系,这些小鼠研究不能转化为临床治疗。总之,在青光眼的临床治疗中使用干细胞将是未来重要的一步,因为它将改变目前的治疗方法,希望能使青光眼患者恢复视力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
0
期刊最新文献
EARLY IDENTIFICATION OF HIGH RISK COVID-19 PATIENTS USING HEMATOLOGICAL INDICES THE IMPACT OF MOVEMENT CONTROL ORDER DURING COVID-19 PANDEMIC ON HEALTHCARE UTILISATION: HOW DOES THE PROJECTED PATIENT WORKLOAD COMPARED TO THE ACTUAL NUMBER OF PATIENTS IN CARE? AGE DIFFERENCE AND PSYCHOLOGICAL FACTORS THAT ARE ASSOCIATED WITH ADOPTION RATE OF PROTECTIVE MEASURES AGAINST COVID-19 IN MALAYSIA MENTAL HEALTH AMONG HOSPITAL STAFF DURING THE COVID-19 PANDEMIC IN A THAI UNIVERSITY HOSPITAL UPDATE ON RAPID DIAGNOSTIC TESTING FOR COVID-19
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1